Pharmacovigilance Market Analysis and Reports | Switzerland Conference Series

Market Analysis - Pharmacovigilance 2020

Global Pharmaceutical Market 2019 Industry Research Report is a professional and in-depth study on the current state of the Global Pharmaceutical industry. This report studies Global Pharmaceutical in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India with production, revenue, consumption, import and export in these regions, from 2014 to 2019, and forecast to 2025.

The global pharmacovigilance market size is expected to reach USD 11.64 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 13.3% during the forecast period. Increasing incidence of Adverse Drug Reactions (ADR) is the key growth driver. The U.S. Food and Drug Administration (FDA) received approximately 253,017 serious adverse events and 44,693 deaths associated with ADRs in 2015. This shows the potential demand for implementing safety and Pharmacovigilance (PV) services.

According to the World Health Organization’s (WHO) report on pharmaceuticals consumption, medicines to treat chronic diseases accounted for a larger proportion of the total volume of drug consumption in non-hospital set ups. Owing to this, there has been a significant rise in the number of medicines made available to healthcare consumers. Rising demand for drugs has significantly heightened the need for the development of novel therapeutics via extensive clinical trials, which is expected to serve this market with lucrative opportunities.

Major pharmaceutical companies are involved in extensive R&D initiatives for development of innovative therapeutic molecules. This has resulted in increased drug development activities. Manufacturers are now focusing on remodeling their product development processes in an attempt to cater to patient needs across the globe. These factors are anticipated to fuel the demand for pharmacovigilance services during the forecast period.

Moreover, leading pharma companies in developed countries are focusing on outsourcing PV service in an attempt to reduce cost and to minimize operational expenses. This is anticipated to serve as an opportunity for contact research organizations in developing regions to gain more revenue share.

The companies operating in the pharmacovigilance market are undertaking strategic initiatives such as collaborations with the PV service providers to gain access to medical information and to manage PV workflows. For instance, In April 2017, Accenture entered in a collaborative agreement with BioCelebrate to develop a platform for aggregating and analyzing clinical information for improved drug developing efficiency, thus enhancing its R&D capabilities. These factors are anticipated to fuel the market growth.

Importance and Scope:

Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem. The main purpose of pharmacovigilance is to improve the patient's safety and enhance his care in terms of the use of medicines, including paramedical interventions. Pharmacovigilance also supports public health programs by providing reliable information for the efficient assessment of the risk-benefit profile of medicines, contribute to the assessment of benefits, uses, side effects, harm, effectiveness and risk of medicines, encouraging the safe, rational and more effective (including cost-effective) use of various medicines. Promote education, understanding and clinical training in Pharmacovigilance and its effective availability to the public. Additionally, health regulatory authorities such as the U.S. FDA and EMEA (European Medicines Agency) are now emphasizing on electronic submission of data which is also expected to drive the pharmacovigilance market.

Pharmacovigilance Market, by Phases of Drug Development:

  • Preclinical Studies                                                              
  • Phase I
  • Phase II
  • Phase III
  • Phase IV or Post Marketing Surveillance  

Pharmacovigilance Market, by Type of Methods:

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

Pharmacovigilance Market, by Type of Service:

  • In-House
  • Contract Outsourcing

Target Audience:

  • Pharmacovigilance Students, Scientists
  • Pharmacovigilance Researchers
  • Pharmacovigilance Faculty
  • Medical Colleges
  • Pharmacovigilance Associations and Societies
  • Business Entrepreneurs
  • Training Institutes
  • Software Developing Companies
  • Manufacturing Medical Devices Companies
  • Data Management Companies

Related Companies/Industries:



Johnson & Johnson





Eli lily






Boehringer Ingelheim

Bristol-Myers Squibb

Takeda Pharmaceutical


Novo Nordisk

Gilead Sciences

Biogen Idec









Association & Societies:

  1. International Society of Pharmacovigilance & Drug Safety
  2. Association of Clinical Research Professionals (ACRP)
  3. American Association of Pharmaceutical Scientists
  4. Association of British Pharmaceutical Industry
  5. Society of Clinical Research Associates (SOCRA)
  6. Canadian Association of Professionals in Regulatory Affairs Clinical Research Society (CRS)
  7. European Association for Clinical Pharmacology (EACPT)
  8. International Society of Pharmacovigilance (ISOP)
  9. Pharmaceutical Information and Pharmacovigilance Association (PIPA)
  10. Association of CROs Czech Republic (ACRO-CZ)
  11. European Clinical Research Infrastructures Network (ECRIN)
  12. European Society for Clinical Investigation (ESCI).
  13. International Society of Pharmacovigilance: (ISOP)
  14. Indian Society for Clinical Organization Research (ISCR)
  15. Indian Society for Clinical Research 
  16. The Society of Clinical Research Associates 
  17. Association of Clinical Research Organization
  18. Japan CRO Association (JCROA)
  19. Pan-Asian Clinical Research Association (PACRA)
  20. Central Society for Clinical and Translational Research (CSCTR)

Conference Series is organizing splendorous Pharmaceutical conferences welcomes you to attend the 13th International Conference and Exhibition on Pharmacovigilance & Drug Safety to be held during July 27-28, 2020 in Zurich, Switzerland. It focuses on the advancements in Pharmacovigilance, Risk Management, and Drug Safety.
The field of Pharmacovigilance is growing rapidly and its development is making tremendous impacts in medical sciences and pharmaceuticals. 13th International Conference and Exhibition on Pharmacovigilance & Drug Safety  emphasizes on how the importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence various sectors. 
Why to attend???
With members from around the world focused on learning about Pharmacovigilance and its advances; this is your best opportunity to reach the largest assemblage of participants from the Pharmacovigilance community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive named recognition at this 2-days event. World-Renowned Speakers, the most recent techniques, developments, and the newest updates in Pharmacovigilance are Hallmarks of this Conference.
Target Audience:
  • Pharmacovigilance Students, Scientists
  • Pharmacovigilance Researchers
  • Pharmacovigilance Faculty
  • Medical Colleges
  • Pharmacovigilance Associations and Societies
  • Business Entrepreneurs
  • Training Institutes
  • Software Developing Companies
  • Manufacturing Medical Devices Companies
  • Data Management Companies